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 Management commentary 
 Michael  Berk 
 h ere can be few psychiatric or medical disorders where the disparity between the attention 
given to a disease, its actual prevalence and its disease burden is greater than in BP II. As 
a boundary disorder, straddling the gap from classical BP I to unipolar major depression, 
and overlapping with borderline personality and ADHD amongst others, it has lain in the 
research shadow of both, attracting minimal independent focus. h is is despite its substantial 
prevalence, complexity and morbidity. 
 It is perhaps prudent to preface any discussion about this diagnostic category by 
standing back and looking at diagnoses more broadly. In no other branch of medicine does 
pathophysiology linearly track phenomenology, yet we are limited to phenomenological-
based diagnostic boundaries. Biomarkers have shown scant respect for the most commonly 
used diagnostic categories, and treatments too have minimal diagnostic specii city. h e only 
clear caveat perhaps is lithium, whose proi le of ei  cacy is in the domain of classical bipolar 
disorder and the cyclical recurrent mood disorders. For the rest, we need to acknowledge 
that we are parsing the clouds on an overcast day. h e counterpoint is that we need to make 
major clinical and treatment decisions on the basis of a very incomplete evidence base, 
drawing on the basis of experience, interpretation and bias simultaneously from the bipolar 
and unipolar literature, without a clear pathophysiological foundation. 
 Diagnostic boundaries: treatment implications 
 In order to make a DSM-IV-TR diagnosis of BP II, a history of at least one major depressive 
episode and one hypomanic episode, in the absence of any manic or mixed episodes, is 
required (APA,  2000 ). In essence, the diagnosis hinges on the presence of hypomania, and 
the criteria for hypomania are hotly debated. A hypomanic episode dei ned by the DSM-
IV-TR needs to consist of persistently elevated, expansive or irritable mood lasting for at 
least 4 days, during which the patient must have at least three (four if mood is irritable) 
of the following symptoms: inl ated self-esteem or grandiosity, decreased need for sleep, 
talkativeness or pressure to keep talking, l ight of ideas or subjective experience of racing 
thoughts, distractibility, increase in goal-directed activity or psychomotor activation and 
excessive involvement in pleasurable activities. h e 4-day criterion is under debate in the 
context of the launch of the DSM-V (Suppes,  2011 ). h is raises the clinically critical question 
as to what is an appropriate duration of hypomania required to trigger a BP II diagnosis? 
 Brief periods of hypomania are common in both BP I and BP II sub-types (Bauer  et al., 
 2006 ). When examining illness characteristics such as age of onset, family history, depressive 
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duration, suicide attempts and conduct problems, Angst showed hypomanic episodes of 1 
to 3 days’ duration to be of comparable signii cance to those lasting 4 days or more (Angst 
 et al .,  2003 ). h ere are proponents of shortening the duration criterion for diagnosis from 
4 to 2 days (Akiskal and Pinto,  1999 ), and there has been an argument for not using a i xed 
duration criterion at all (Angst  et al .,  2003 ). Cassano and colleagues ( 2004 ) showed that 
manic symptoms occurred in a graded and spectral manner in those with recurrent major 
depression, and without a clear point of inl exion. 
 More recent evidence derives from the bridge study (Angst,  2011 ). In this large study 
of 5635 people with major depressive episodes (MDE) from 18 countries, the hypomania 
checklist was applied to validate a new proposed criterion for bipolarity, the bipolar specii er. 
In this study, using DSM-IV criteria, 31% had a bipolar and 69% had a MDE diagnosis. Using 
the bipolar specii er, the percentages were 47% and 53%, respectively, and when using the 
hypomania checklist, the proportions shit ed again to 54% and 46%, respectively. A longer 
duration of hypomania was associated with a graded increase in the proportion of people 
with a positive family history of mania, early onset, a recurrent pattern, a seasonality pattern, 
antidepressant-related switching, atypical features and suicidal attempts, without any clear 
threshold being evident. In addition, far greater comorbidity was seen in BP II than in MDE. 
 h ere are a number of treatment implications to these data, with them suggesting i rstly 
that BP II is not simply a milder version of bipolar disorder, and may actually be a more 
complex disorder with greater comorbidity and that it merits particularly active management. 
Secondly, hypomania appears to exist on a continuum in terms of duration. h e greater 
rates of antidepressant-related switch with longer durations of hypomania have signii cant 
treatment implications, especially in the context of the paucity of treatment options. For 
those with brief or sub-threshold hypomania, the risks of antidepressant therapy may be 
less than for those with threshold hypomania, supporting more liberal use of particular 
antidepressant agents in that group . 
 Mixed states 
 A diagnosis of a mixed state requires the concurrent presence of threshold mania and 
depression. h is, by dei nition, excludes the diagnosis of mixed episodes in BP II, an omission 
that has been cogently argued by Benazzi ( 2007 ) among others. h is is likely to be remedied 
in the DSM-V classii cation. h e presence of sub-threshold manic symptomatology in 
the context of depression has important treatment and prognostic implications, not least 
in predicting diagnostic shit  from unipolar to bipolar disorder (Fiedorowicz  et al. ,  2011 ). 
Zimmerman and colleagues ( 2009 ) have reported a 10-year prospective study ( n = 2210), 
dei ning sub-threshold bipolar disorder as MDD together with hypomanic symptoms, but 
never having met criteria for (hypo)mania. Among 488 respondents with MDD, 60% had 
pure MDD and 40% had sub-threshold bipolar disorder.  h e sub-threshold BD cases had 
a signii cantly increased family history of mania, and higher rates of nicotine dependence, 
alcohol use disorders and panic disorder. Sub-threshold cases were more likely to convert to 
bipolar disorder. If there are pitiful data to guide management of BP II disorder in general, 
there is almost a total vacuum in terms of BP II mixed states. In general, it is probably 
prudent to follow the approaches outlined in evidence-based guidelines, such as the 
CANMAT/ISBD guidelines. Many people with antidepressant-induced mixed states report 
them as depressive, and careful history taking can parse two forms of ‘depression’ in a BP 
II individual; an anergic l at and atypical depression, and an agitated, anxious, irritable 
state with insomnia. A further important management implication of this i nding is that, 
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in individuals with ‘pure’ l at, atypical or anergic depression, one may consider therapy that 
dif ers from the management of activated, agitated or mixed depression. h e latter group 
would best be managed with atypical antipsychotics, lithium and anticonvulsants, while 
antidepressants, on a mood stabiliser foundation, may be considered for the anergic group. 
 Hypomania associated with substance use and antidepressant drugs is characteristically 
dysphoric and mixed, resulting in overlap and confusion with depressive phenotypes. DSM-IV 
does not recognise drug- or antidepressant-induced hypomania, complicating recognition. 
DSM-IV makes things worse, necessitating the presence of threshold mania and depression 
for diagnosis of a mixed state, tautologically negating the presence of a mixed bipolar state in 
BP II – since full mania is, by dei nition, only present in BP I disorder. h is will be remedied 
in the next iteration of the DSM. Nevertheless, this limitation belies the common observation 
that antidepressants can induce subtle mixed states, and thereby aggravate the core cyclical 
pattern of the disorder. However, this is not captured by routinely used instruments, leading 
to the possible erroneous minimisation of risk. h ere is, in addition, an overt conl ict of 
interest with regards to the commonly used threshold for induction of mania and mixed 
states. It is in the interests of the pharmaceutical industry to have a very high threshold for 
the detection of adverse events, especially those where links to therapy are more opaque, 
and a passive collusion in the acceptance of a threshold that will result in a very low rate of 
detection of adverse events. 
 h e notion of antidepressant-induced mixed states is also informed by what we have 
observed with antidepressant-induced sexual dysfunction. When relying on self-report, 
antidepressant-induced sexual dysfunction was thought to be a rare issue; however, its true 
scale was only appreciated when using formal and structured instruments, and when it was 
then appreciated that it occurs in over 50% of treated individuals. h ere is no  a priori measure 
for antidepressant-induced mixed states or cycle aggravation, and, in the absence of a formal 
measure and mere reliance on self-reports, it is highly probable that the true prevalence will 
be under-estimated.  Akin to this concern, there are many reports of cycle acceleration with 
antidepressants, yet no standardised metric for prospectively measuring the characteristics 
of the cyclical process routinely used in most clinical trials. h is is a major omission from 
current practice, and such data are urgently needed to coni rm or deny the possibility that 
pharmacotherapy can modulate the core process of cyclicity in benei cial or harmful ways . 
 Diagnostic changes and management implications 
 Recently, changes have been suggested for the core phenotype of BP II. Data suggests that over-
activity is the most common and most strongly correlated hypomanic symptom in BP II disorder. 
It has been argued that this should be a stem criterion for hypomania (Benazzi,  2006 ), and is 
likely to be adopted in the DSM-V system. While viewed as a minor change – as it is implicit in 
the DSM-IV system – it will add clarity, that increased activity or energy is a core symptom of 
mania and hypomania. h e management implications of this i nding are more distal; however, 
it points to the new research focus on energy and energy generation at a mitochondrial level as 
a potential treatment target. h is is more a focus for future research than for current practice. 
 As a syndromal phenomenon, BP II disorder can be dii  cult to diagnose. h is is suggested 
by its lengthy mean lag time to diagnosis, which has been estimated to be several years longer 
than in BP I (Ghaemi  et al .,  2000 ; Mantere  et al.,  2004 ). h is diagnostic elusiveness may have 
a number of explanations relating to features of the disorder, the patient and the clinician. 
Since the disorder has a typical depressive onset, diagnostic uncertainty is predictable (Berk 
 et al.,  2007 ) and there is a predominance of depressive episodes over the longitudinal course, 
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which may initially present as a unipolar type depression. h e misleading nature of initial 
bipolar presentations is spotlighted by longitudinal follow-up studies. h ese have consistently 
shown a steady and linear pattern of transition from unipolar to bipolar diagnoses, over 
extended periods of time. In a study by Angst and colleagues ( 2005 ) conducted over a 23.4-
year mean duration, 50% of those initially diagnosed with unipolar disorder switched to a 
bipolar diagnosis (32.1% BP I, 17.9% BP II). A coni rmatory study by Goldberg  et al . ( 2001 ) 
noted that 27% of patients with unipolar depression developed hypomania over a 15-year 
follow-up period. Both studies illustrated a steady, linear and age-independent transition 
pattern, suggesting an ongoing risk for transition with time. From a treatment perspective, 
the presence of latent bipolarity among individuals with depressive index presentations 
is common, and may explain part of the heterogeneity in treatment outcomes. Data on 
the phenomenological dif erences between unipolar and bipolar disorder – the so-called 
‘bipolar signature’ – may be useful to guide treatment decisions in situations where there is 
diagnostic ambiguity. 
 Such concerns are further compounded by the overwhelming predominance of patients 
seeking treatment for depression rather than hypomania, and under-recognising and 
under-reporting of hypomanic symptoms, a feature emphasised in the preceding chapters. 
Under-reporting may relate to impaired insight into the presence of hypomania. h is could 
be due to the subtle quality or brief duration of hypomania, the ot en distorted af ective 
reference point of patients with mood disorders, or to a view of hypomania as a reprieve 
from depression. An additional confound is that, by dei nition, hypomania is frequently 
not impairing nor distressing, increasing the chance that it may be viewed as normal, 
and even desirable, further complicating recognition. For a variety of reasons, including 
time restrictions, educational factors, psychiatric expertise and availability of collateral 
historical accounts, clinicians may fail to specii cally enquire about hypomania or recognise 
its presence. For these reasons, hypomania is almost never the presenting clinical state in 
BP II, and pragmatically, management of hypomania is very rarely the focus of treatment. 
Paradoxically, hypomania is very simple to manage, being essentially self-limiting and 
responsive to standard anti-manic agents. 
 Comorbidity 
 Personality factors, anxiety and substance use commonly co-exist with mood disorders, 
which may further obscure diagnostic clarity and complicate management. Depression is 
heterogeneous, and this is true for BP II as well. Not all unhappiness is due to the core 
biology of the disorder, and comorbidity is a common driver. Pragmatically, a formulation-
based approach to conceptualising depression rather than rigid use of algorithms is 
necessary. Personality and substance use are singularly capable of driving dysphoric mood, 
and if clinical formulation weights their contribution, management should follow. In an 
individual with dysphoric mood, and a diagnosis of BP II and borderline traits, dialectical 
behaviour therapy (DBT) or other personality-focussed therapy may be far more ei  cacious 
than algorithm-derived pharmacotherapy. Similarly, management of comorbid substance 
use is ot en the shortest route to euthymia in those with that comorbidity. 
 Staging 
 Stage of illness may matter. h ere is a body of literature suggesting that lithium response 
is greater early in the course of illness, and declines serially with recurrence. Similarly, in a 
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trial of CBT, Scott  et al. ( 2006 ) noted that those individuals who had fewer than i ve episodes 
benei ted from CBT, whereas those who had endured over 30 episodes actually worsened with 
CBT.  We have analysed data from the STEP BD antidepressant trial, examining for staging 
ef ects. It was clear that, for individuals who had multiple prior episodes of illness, there was 
no ef ect at all of antidepressant therapy. h ere was a curious trend (albeit not statistically 
signii cant), suggesting that there was indeed a transient reduction in depression symptoms 
lasting a few months in those who were in the earliest stages of illness. h is concords with 
clinical observations that people may have an initial response to antidepressants early in 
their illness course, but that ‘poop out’ frequently follows. A possible hypothesis for this 
phenomenon is that antidepressants may nudge an inherently unstable mood regulatory 
system initially in the desired direction, but that activation of homeostatic or compensatory 
regulatory systems, as well as activation of the cascade of neuroprogression, may lead to 
treatment resistance and/or aggravation of the underlying pattern of cyclicity. h ere are recent 
data that antidepressant therapy may result in enduring changes in the cyclical pattern of the 
illness (Strejilevich  et al. ,  2011 ). While this all remains uncertain and hypothetical, I agree 
with the position of Ketter and Wang that ‘the role of adjunctive antidepressants in acute 
bipolar depression may need to be reconsidered’. A fascinating insight into the mechanism of 
neuroprogression is unpublished data from Maes and colleagues (personal communication, 
2011), who found that oxidative and nitrosative stress results in damage to proteins, lipids 
and neurotransmitters, leading to immunogenically altered neo-epitopes that trigger an auto-
immune response, damaging intracellular constituents and processes in a manner that may 
drive persistent illness. h e precautionary principle suggests that, while the benei ts and risks 
of antidepressants remain uncertain, other i rst-line therapies should take preference. 
 A way of conceptualising BP II management is that of foundation therapies and 
add-on therapies. h e former ideally should consist of those mood stabilisers that are of 
documented ei  cacy in the disorder. Maintenance, and hence reduction of cyclicity, should 
be the primary goal of therapy. h is is, by dei nition, long-term management, augmented by 
add-on therapies targeted at state perturbations or comorbidity issues. 
 Lastly, there is an increasing body of data indicating that lifestyle plays a role in the 
genesis of psychiatric disorders, and that addressing these lifestyle factors may be of value 
in clinical management. One’s level of physical activity plays a role in the risk for developing 
mood disorders (Jacka  et al. ,  2011 ), and there is a large and validated evidence base for 
exercise as a therapeutic modality in depression, as well as some evidence in bipolar disorder 
(Ng  et al. ,  2007 a,b). Given the high comorbidity of BP II with other lifestyle-related non-
communicable disorders, routine prescription of an exercise programme compatible with 
the person’s stage of life would appear to be indicated on the grounds of primary ei  cacy, cost 
and value in comorbidity. Similarly, smoking and substance misuse appear to be clear risk 
factors for mood disorders, while simultaneously worsening the outcome and likelihood of 
treatment response to conventional mood stabilisers (Dodd  et al .,  2010 ). Smoking cessation 
should be an active goal of therapy in all smokers, although it is probably prudent to time this 
outside of acute episodes of illness. h e link between alcohol, and risk for and outcome of 
mood disorders, is far weaker except in true alcohol abuse or dependence, and interventions 
need to be restricted to the latter groups (Coulson  et al .,  2010 ). h ere is new epidemiological 
evidence that diet is a risk factor for depression; good-quality diets appear protective and 
poor diet increases risk (Jacka  et al .,  2009 ,  2010 a,b). Surprisingly, this association appears 
even stronger in bipolar than in unipolar disorder (Jacka  et al .,  2011 ). Again, this message 
needs to be communicated, and individuals assisted with healthy eating choices. h ere is 
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some evidence that augmentation with omega-3 fatty acids may be of value, and there is new 
placebo-controlled data that augmentation with  N -acetyl cysteine, which is of value in BP I 
disorder, may be associated with higher remission rates in BP II (Berk  et al .,  2008 ; Magalhaes 
 et al.,  2011 ). Attention to lifestyle factors, and lifestyle modii cation as indicated, may be of 
substantial value in reducing the burden of depression in individuals . 
 Conclusions 
 BP II is a highly prevalent disorder, which is asymmetrically neglected as a research focus. 
h ere remain many gaps in the understanding of its diagnosis, aetiology and treatment. 
From a management perspective, there is a paucity of adequate quality clinical trial data 
to guide practice, an issue that is made more complex by the uncertain risks of iatrogenic 
aggravation of the inherent cyclical process of the disorder by the most commonly used 
medication group, antidepressants. In the absence of BP II-specii c treatment data, it remains 
unclear if management is best based on extrapolation of the evidence base for unipolar or BP 
I treatments. BP II needs to be a priority for clinical trial development and, until quality data 
are available to better guide management, a cautious and vigilant approach to treatment of 
this complex condition appears warranted. 
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